… system during pregnancy, as well as its anti-fibrotic and anti-… effective than the ACE inhibitor
enalapril in reducing cardiac … experimental design in pre-clinical studies versus clinical trial …

… Heart Association acute heart failure activin receptor-like kinase analysis of variance activator
protein 1 angiotensin-receptor-neprilysin-inhibitor angiotensin 2 adenosine triphosphate …

… in the majority of cardiovascular diseases and is a key … to reduce organ fibrosis in various
experimental models. (47,48) … such as ARBs and ACE inhibitors that may provide additional …

… , compared with the effects of the ACE inhibitor, perindopril. … impact of the experimental
model established on animal … can augment the anti-fibrotic efficacy of serelaxin over shorter …

… BM-MSCs with the anti-fibrotic drug serelaxin (RLX), have … intrarenal RAAS activity, including
ACE inhibitors (ACEi) and … -hypertensive effects in experimental models of hypertensive …

… significant clinical conditions such as hypertension, heart failure, … The alternative RAAS
pathway exerts anti-fibrotic actions through … AT1R blockers (ARBs), ACE inhibitors, and selective …

… its therapeutic efficacy to the ACE inhibitor, … as serelaxin, the drug-based version of H2
relaxin) has been found to exert rapid-occurring anti-inflammatory, anti-hypertrophic, anti-fibrotic, …

… of cardiac and renal fibrosis in the CKD and heart failure (HF) … the classic inhibitors (ACE
inhibitors, AT1 antagonists, and … of myofibroblasts to serelaxin and reduce its anti-fibrotic effect […

… The acute heart failure drug, serelaxin (recombinant human … least 4–5 days prior to
experimental models of ALI and AAD. … the efficacy and bioavailability of circulating serelaxin in the …

… thus, determined whether the anti-fibrotic drug, serelaxin (RLX), … a greater extent than either
treatment alone or the ACE inhibitor, … However, due to the impact of the experimental model …